NASDAQ:EKSOEkso Bionics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ekso Bionics Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.55 -0.11 (-4.14 %) (As of 04/5/2020 03:18 AM ET) Add Compare Share Today's Range$2.55Now: $2.55▼$2.7050-Day Range$0.19MA: $0.78▼$3.7552-Week Range$2.25Now: $2.55▼$38.25Volume35,078 shsAverage Volume111,330 shsMarket Capitalization$14.82 millionP/E RatioN/ADividend YieldN/ABeta1.86 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke. The company's Ekso device is primarily used in a hospital and rehabilitation setting. The company has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingEkso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.03, Ekso Bionics has a potential upside of 58.2% from its current price of $2.55.Amount of Analyst CoverageEkso Bionics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesEkso Bionics has received 292 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEkso Bionics has received 248 “underperform” votes. (Add your “underperform” vote.)Community SentimentEkso Bionics has received 54.07% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ekso Bionics and other stocks. Vote “Outperform” if you believe EKSO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EKSO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEkso Bionics does not currently pay a dividend.Dividend GrowthEkso Bionics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ekso Bionics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 24.30% of the stock of Ekso Bionics is held by insiders.Percentage Held by InstitutionsOnly 34.30% of the stock of Ekso Bionics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ekso Bionics are expected to decrease by -79.49% in the coming year, from ($5.07) to ($1.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ekso Bionics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ekso Bionics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEkso Bionics has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.24 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry General industrial machinery, Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EKSO Previous SymbolOTCMKTS:EKSOD CUSIPN/A CIK1549084 Webhttp://www.eksobionics.com/ Phone510-984-1761Debt Debt-to-Equity Ratio0.16 Current Ratio2.40 Quick Ratio2.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$13.92 million Price / Sales1.06 Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book2.18Profitability EPS (Most Recent Fiscal Year)($3.45) Net Income$-12,130,000.00 Net Margins-87.19% Return on Equity-286.13% Return on Assets-74.74%Miscellaneous Employees77 Outstanding Shares5,810,000Market Cap$14.82 million Next Earnings Date5/6/2020 (Estimated) OptionableNot Optionable Receive EKSO News and Ratings via Email Sign-up to receive the latest news and ratings for EKSO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EKSO Rates by TradingView Ekso Bionics (NASDAQ:EKSO) Frequently Asked Questions How has Ekso Bionics' stock been impacted by COVID-19 (Coronavirus)? Ekso Bionics' stock was trading at $0.2616 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EKSO stock has increased by 874.8% and is now trading at $2.55. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Ekso Bionics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ekso Bionics. When is Ekso Bionics' next earnings date? Ekso Bionics is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Ekso Bionics. How were Ekso Bionics' earnings last quarter? Ekso Bionics Holdings Inc (NASDAQ:EKSO) announced its earnings results on Thursday, February, 27th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The firm earned $3.72 million during the quarter. Ekso Bionics had a negative net margin of 87.19% and a negative return on equity of 286.13%. View Ekso Bionics' earnings history. When did Ekso Bionics' stock split? How did Ekso Bionics' stock split work? Ekso Bionics shares reverse split before market open on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split. What guidance has Ekso Bionics issued on next quarter's earnings? Ekso Bionics issued an update on its FY 2019 Pre-Market earnings guidance on Friday, January, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $13.9-13.9 million, compared to the consensus revenue estimate of $13.77 million. What price target have analysts set for EKSO? 3 brokerages have issued 12-month price objectives for Ekso Bionics' stock. Their forecasts range from $1.20 to $8.00. On average, they expect Ekso Bionics' share price to reach $4.03 in the next twelve months. This suggests a possible upside of 58.2% from the stock's current price. View analysts' price targets for Ekso Bionics. What are Wall Street analysts saying about Ekso Bionics stock? Here are some recent quotes from research analysts about Ekso Bionics stock: 1. According to Zacks Investment Research, "Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company's operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. " (4/1/2020) 2. Aegis analysts commented, "We think conversion rate is an interesting metric to follow as it is representative of accounts which trialed the Ekso GT via the rental program, and then decided to make the capital commitment, which is significant, at around $130K per Ekso GT." (8/8/2019) Has Ekso Bionics been receiving favorable news coverage? Media coverage about EKSO stock has trended very negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ekso Bionics earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutEkso Bionics. Are investors shorting Ekso Bionics? Ekso Bionics saw a increase in short interest in March. As of March 13th, there was short interest totaling 4,900,300 shares, an increase of 5.8% from the February 27th total of 4,630,000 shares. Based on an average trading volume of 788,300 shares, the days-to-cover ratio is currently 6.2 days. Approximately 8.0% of the shares of the stock are sold short. View Ekso Bionics' Current Options Chain. Who are some of Ekso Bionics' key competitors? Some companies that are related to Ekso Bionics include Otonomy (OTIC), Immunic (IMUX), Edap Tms (EDAP), Orgenesis (ORGS), Aldeyra Therapeutics (ALDX), Patient Home Monitoring (PTQ), Corvus Pharmaceuticals (CRVS), United-Guardian (UG), Immunodiagnostic Systems (IDH), Proteostasis Therapeutics (PTI), Pluristem Therapeutics (PSTI), Vaccinex (VCNX), Xeris Pharmaceuticals (XERS), Sesen Bio (SESN) and Orthocell (OCC). What other stocks do shareholders of Ekso Bionics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include TransEnterix (TRXC), XOMA (XOMA), Infinity Augmented Reality (ALSO), Opko Health (OPK), Editas Medicine (EDIT), NVIDIA (NVDA), Innovative Industrial Properties (IIPR), Canopy Growth (CGC), Uranium Energy (UEC) and Micron Technology (MU). Who are Ekso Bionics' key executives? Ekso Bionics' management team includes the following people: Mr. Steven A. Sherman, Exec. Chairman (Age 73)Mr. Jack Peurach, Pres, CEO & Director (Age 53)Mr. John F. Glenn, CFO & Sec. (Age 57)Mr. William Shaw, Chief Commercial Officer (Age 45)Ms. Foon Lim Chwee, Pres of APAC What is Ekso Bionics' stock symbol? Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO." How do I buy shares of Ekso Bionics? Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ekso Bionics' stock price today? One share of EKSO stock can currently be purchased for approximately $2.55. How big of a company is Ekso Bionics? Ekso Bionics has a market capitalization of $14.82 million and generates $13.92 million in revenue each year. The company earns $-12,130,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis. Ekso Bionics employs 77 workers across the globe. View additional information about Ekso Bionics. What is Ekso Bionics' official website? The official website for Ekso Bionics is http://www.eksobionics.com/. How can I contact Ekso Bionics? Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected] This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: Calculating net profit and net profit margin ratio
